REPORT DOCUMENTATION PAGE					Form Approved		
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instruction				iewing instructions, sea	arching existing data sources, gathering and maintaining the		
data needed, and completing this burden to Department of I 4302. Respondents should bu valid OMB control number P	and reviewing this collection of a Defense, Washington Headquar a aware that notwithstanding an <b>FASE DO NOT RETURN YOU</b>	ters Services, Directorate for Ir y other provision of law, no per	egarding this burden estimate or a nformation Operations and Reports son shall be subject to any penalty DBESS	iny other aspect of this s (0704-0188), 1215 Je y for failing to comply w	collection of information, including suggestions for reducing ifferson Davis Highway, Suite 1204, Arlington, VA 22202- iith a collection of information if it does not display a currently		
1. REPORT DATE (DI 2005	D-MM-YYYY)	2. REPORT TYPE	DALUU.	3. DATES COVERED (From - To)			
4. TITLE AND SUBTIT	rLE I	open Enerature		58	a. CONTRACT NUMBER		
Protection against se	oman or VX poisonir	ng by human butyryl	cholinesterase in	_			
guinea pigs and cyn	omolgus monkeys			51	D. GRANT NUMBER		
				50	2. PROGRAM ELEMENT NUMBER		
6. AUTHOR(S)	DM Kaplavitz I.C	lark CB Canadia I	DR Caracali DM Ead	sulta IM	I. PROJECT NUMBER		
Luo, C, Saxena, A,	Doctor, BP, Olson, C	liark, CK, Capacio, r	SK, Cerason, DM, Fed	50 Serko, JIVI,	. TASK NUMBER		
				51	5f. WORK UNIT NUMBER		
7. PERFORMING OR	GANIZATION NAME(S)	AND ADDRESS(ES)		8.	PERFORMING ORGANIZATION REPORT NUMBER		
US Army Medical I Chemical Defense	Research Institute of	Aberdeen Pro 21010-5400	oving Ground, MD	U	SAMRICD-P05-005		
ATTN: MCMR-CD	R-I	21010 5100					
3100 Ricketts Point	Road						
9. SPONSORING / MC		AME(S) AND ADDRE	SS(ES)	10	). SPONSOR/MONITOR'S ACRONYM(S)		
US Army Medical F	Research Institute of	Aberdeen Pro	oving Ground, MD				
ATTN: MCMR-CD	A-T	21010-3400		11	11. SPONSOR/MONITOR'S REPORT		
3100 Ricketts Point	Road				NUMBER(S)		
12. DISTRIBUTION / A		IENT					
Approved for public	release: distribution	unlimited					
Approved for public	release, distribution	ummitted					
	VNOTES						
Published in Chemic	co-Biological Interac	tions, 157-158, 205-	210, 2005.				
14 40070407							
See reprint.							
<b>15. SUBJECT TERMS</b> Butyrylcholinesteras	se, soman, VX, guine	a pig, cynomolgus n	nonkey				
16. SECURITY CLASS	SIFICATION OF:		17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	<b>19a. NAME OF RESPONSIBLE PERSON</b> David E. Lenz		
a. REPORT UNLIMITED	<b>b. ABSTRACT</b> UNLIMITED	c. THIS PAGE UNLIMITED	UNLIMITED	6	19b. TELEPHONE NUMBER (include area code)		
					410-430-3323		



Available online at www.sciencedirect.com



Chemico-Biological Interactions 157-158 (2005) 205-210

Chemico-Biological Interaction/

www.elsevier.com/locate/chembioint

# Protection against soman or VX poisoning by human butyrylcholinesterase in guinea pigs and cynomolgus monkeys

David E. Lenz<sup>a,\*</sup>, Donald M. Maxwell<sup>a</sup>, Irwin Koplovitz<sup>b</sup>, Connie R. Clark<sup>a</sup>, Benjamin R. Capacio<sup>a</sup>, Douglas M. Cerasoli<sup>a</sup>, James M. Federko<sup>c</sup>, Chunyuan Luo<sup>c</sup>, Ashima Saxena<sup>c</sup>, Bhupendra P. Doctor<sup>c</sup>, Carl Olson<sup>d</sup>

<sup>a</sup> Pharmacology Division, 3100 Ricketts Pt. Rd., US Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, MD 21010, USA

<sup>b</sup> Drug Assessment Division, 3100 Ricketts Pt. Rd., US Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, MD 21010, USA

<sup>c</sup> Division of Biochemistry, 503 Robert Grant Road, Walter Reid Army Institute of Research, Silver Spring, MD 20910, USA <sup>d</sup> Battelle, 505 King Ave., Columbus, OH 43201, USA

Available online 9 November 2005

### Abstract

Human butyrylcholinesterase (HuBuChE), purified from outdated human plasma, is being evaluated for efficacy against nerve agents in guinea pigs and cynomolgus monkeys. Previous studies in rodents and nonhuman primates demonstrated that pretreatment of animals with enzymes that can scavenge nerve agents could provide significant protection against behavioral and lethal effects of nerve agent intoxication. In preparation for evaluation of efficacy of HuBuChE prior to initiating an investigational new drug (IND) application, the pharmacokinetics of HuBuChE were evaluated in guinea pigs and in cynomolgus monkeys. HuBuChE was injected intramuscularly (i.m.) at two doses, and blood samples were taken to follow the time-course of HuBuChE in blood for up to 168 h after administration. In guinea pigs, the two doses of HuBuChE, 19.9 and 32.5 mg/kg, produced similar times of maximal blood concentration ( $T_{\text{max}}$  of 26.0 and 26.8 h, respectively) and similar elimination half-times ( $t_{1/2}$  of 64.6 and 75.5 h, respectively). Enzyme levels were still 10-fold over baseline at 72 h. Based on these data, guinea pigs were administered 150 mg/kg of enzyme i.m. and challenged at  $T_{max}$ . Soman or VX doses were approximately 1.5, 2.0 and 2.0 × LD<sub>50</sub> administered subcutaneously (s.c.) in sequence at 90-120 min apart. None of the animals displayed signs of organophosphorus (OP) anticholinesterase intoxication at any of the challenge levels, and all survived for the 14-day duration of the experiment. Similar experiments were carried out with cynomolgus monkeys to determine the pharmacokinetics of HuBuChE and its efficacy against soman. The complete survival of nearly all animals tested to date, coupled with the maximal blood concentration and half-life elimination profile obtained for HuBuChE after i.m. injection, provides strong support for the continued development of HuBuChE as a product to protect against nerve agents. © 2005 Elsevier Ireland Ltd. All rights reserved.

Keywords: Butyrylcholinesterase; Soman; VX; Guinea pigs; Cynomolgus monkey

## 1. Introduction

\* Corresponding author. Tel.: +1 410 436 3525;

fax: +1 410 436 8377.

While successful, current treatments for acute nerve agent poisoning always result in the victim suffering a toxic insult that subsequently must be therapeutically managed. In contrast, recent efforts have focused on identifying proteins that can remain stable in circula-

E-mail address: david.lenz@amedd.army.mil (D.E. Lenz).

<sup>0009-2797/\$ -</sup> see front matter © 2005 Elsevier Ireland Ltd. All rights reserved. doi:10.1016/j.cbi.2005.10.025

tion for long periods of time [1-3] and act as biological scavengers of OP compounds. This approach avoids the side effects associated with current antidotes [4-12] and the requirement for their rapid administration, by prophylactically inactivating (through sequestration or hydrolysis) anticholinesterase agents before they can react with the target acetylcholinesterase (AChE). The time frame for this inactivation to occur before endogenous AChE is affected is guite narrow (estimated to be approximately 2 min in humans [13]). For acute OP exposures, the scavenger function must be very rapid, irreversible and specific. Ideally, the scavenger should enjoy a long residence time in the blood stream, should be biologically innocuous in the absence of nerve agent, and should not present an antigenic challenge to the immune system. For these reasons, prime efforts to identify candidate bioscavengers have focused recently on HuBuChE. In a series of studies, Ashani and coworkers [14-16] examined the scavenger properties of FBS AChE and HuBuChE in mice, rats and rhesus monkeys with respect to several different nerve agents as well as other OP compounds. The main focus of those studies was to demonstrate that HuBuChE was capable of affording protection against OP poisoning as measured by the lack of behavioral deficits. In the final paper in this series [16] the authors reported protection by HuBuChE against a  $3.3 \times LD_{50}$  dose of soman or a  $2.1 \times LD_{50}$  dose of VX in rhesus monkeys. They also reported considerable protection against soman-induced behavioral deficits in a spatial discrimination task. Our current efforts were designed to expand on those observations to include pharmacokinetic studies of HuBuChE in two species, guinea pigs and cynomolgus monkeys, and then evaluate HuBuChE for efficacy against soman and VX poisoning in guinea pigs and against soman in cynomolgus monkeys at up to  $5.5 \times LD_{50}$ doses of each agent in the respective species. Such studies would demonstrate that HuBuChE could confer consistent protection against OP poisoning in multiple species.

## 2. Experimental procedures

## 2.1. Animals

Male Hartley albino guinea pigs (*Cavia porcellus*) (Charles River Laboratories, Kingston, NY), weighing 300–450 g, were used. Animals were quarantined and observed for a minimum of 5 days for evidence of disease in accordance with the stipulations mandated for an Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) accredited facility prior to being put on study. Guinea pig ration and water were provided ad libitum.

Cynomolgus monkeys (3.0–3.5 kg) were held in isolation and observed for signs of clinical illness prior to study initiation. Fluorescent lighting with alternating light and dark cycles of approximately 12 h was provided. Animals were fed twice daily with Purina Certified Monkey Chow<sup>®</sup> biscuits and supplemented with fresh fruit or primate treats. Drinking water was available ad libitum. Personnel handling nonhuman primates (NHP) wore the appropriate personal protective equipment.

#### 2.2. Materials

Soman (pinacolylmethyl phosphonofluoridate) and VX (*O*-ethyl-*S*-(2-isopropylaminoethyl) methylphosphonothiolate) were obtained from the Research Development and Engineering Center, Aberdeen Proving Ground, MD. They were >97% pure by <sup>31</sup>P NMR analysis. The HuBuChE was supplied as a lyophilized powder (700 U/mg) by the Division of Biochemistry at Walter Reed Army Institute of Research. It was dissolved in physiologic saline to the desired concentration immediately before use. Butyrylthiocholine and 5,5'-dithiobis-(2-nitrobenzoic acid) were purchased from Sigma Chemicals (St. Louis, MO).

#### 2.3. Pharmacokinetic studies

Two doses of HuBuChE were injected intramuscularly (i.m.) in either guinea pigs or cynomolgus monkeys to determine its pharmacokinetics in blood. In guinea pigs, the two doses of HuBuChE were 19.9 and 32.5 mg/kg; in cynomolgus monkeys, the two doses of HuBuChE were 5.25 and 8.75 mg/kg. The lower dose in each species was calculated to provide protection against a  $1.5 \times LD_{50}$  soman challenge, while the higher dose was calculated to provide protection against  $2.5 \times LD_{50}$  of soman. HuBuChE was a lyophilized powder in 25 mg aliquots with a specific activity of 700 U/mg. It was reconstituted in physiologic saline to allow for injection volumes of 0.4 or 1.0 mL in guinea pigs and monkeys, respectively. Blood samples were taken in heparinized containers prior to the injection of HuBuChE (by toe clip from guinea pigs and from the femoral vein from cynomolgus monkeys) and at approximately 1, 2, 4, 10, 12, 24, 48, 72, 96, 120, 144, and 192 h after injection. BuChE activity in whole blood samples was measured in blood samples from three guinea pigs or three cynomolgus monkeys in each dose group as a function of time after administration using a microtiter plate modification of the method of Ellman et al. [17]. Butyrylthiocholine was used as the assay substrate, and colorimetric  $(A_{412} \text{ nm})$  responses were detected using a SpectraMax Plus 384 (Molecular Devices, Sunnyvale, CA).

Mean whole blood HuBuChE time-concentration data were fit to standard pharmacokinetic models using WinNonlin nonlinear regression software (version 1.5, 1997, Scientific Consulting Inc., Cary, NC). Pharmacokinetic parameter estimates and predicted HuBuChE concentrations as a function of time were calculated from the raw data using the appropriate mathematical model. The following criteria were utilized as guidelines for determining the appropriate model: minimal sum of squared residuals, high correlation coefficient, small standard deviations of parameter estimates and unbiased distribution patterns of residuals for estimates of observed versus predicted values. Parameter estimates generated were apparent volume of distribution  $(V_d)$ , absorption rate constant  $(k_{01})$ , elimination rate constant  $(k_{10})$ , time to maximum plasma concentration  $(T_{\text{max}})$ , maximum plasma concentration  $(C_{max})$ , and area under the time-concentration curve (AUC).

The pharmacokinetics of HuBuChE after i.m. administration to guinea pigs or cynomolgus monkeys were best described by a one-compartment model with firstorder absorption and elimination described by Eq. (1) (below):

$$C(t) = \frac{D}{V_{\rm d}} \frac{k_{01}}{k_{01} - k_{10}} (e^{-k_{10}t} - e^{-k_{01}t})$$
(1)

where *C* is the plasma concentration (mg/mL), *t* the time (min), *D* the dose (mg/kg),  $V_d$  the volume of distribution (mL/kg),  $k_{01}$  (min<sup>-1</sup>), and  $k_{10}$  (min<sup>-1</sup>).

#### 2.4. Efficacy studies

Guinea pigs (n = 10) were administered HuBuChE i.m., in sufficient quantity to neutralize a  $10-11 \times LD_{50}$ challenge of soman ( $1 \times LD_{50} = 30 \mu g/kg$  s.c.) or VX

Hours

max

OP1+1.5 OP2+1.5

Time

0 (Blood

Samples)

 $(1 \times LD_{50} = 9 \mu g/kg \text{ s.c.})$  based on the stoichiometric equivalence of 1:1 for nerve agent and HuBuChE. At 19 ( $\pm$ 1.0) h after administration, a blood sample was taken via toe clip and the whole blood butyrylcholinestrase (BuChE) concentration was determined. Based on that determination, the total number of moles of BuChE in circulation (endogenous and administered HuBuChE) was calculated assuming a blood volume of 20 mL for a 400 g guinea pig. A molar amount of soman (45  $\mu$ g/kg) or VX (13.5  $\mu$ g/kg) equal to 1.5 × LD<sub>50</sub> was given s.c. and the animal observed for signs of intoxication for 90 min. At the end of that period a second blood sample was taken and the total blood BuChE concentration redetermined. The total number of moles of BuChE in circulation was recalculated, and  $2 \times LD_{50}$  of soman or VX was administered s.c. Again the animal was observed for signs of intoxication for 90 min, and if none were observed the process was repeated one more time. Ninety minutes after the third dose of soman or VX, a final blood sample was taken and analyzed for total blood BuChE concentration. Surviving animals were held for 7 days at which time one-half the surviving population was randomly selected for euthanization followed by histopathology studies. Seven days later (14 days after nerve agent administration) the remaining animals were euthanized for histopathology studies (Fig. 1).

Monkeys were administered HuBuChE, i.m., in sufficient quantity to neutralize an  $8 \times LD_{50}$  challenge of soman (n=6;  $1 \times LD_{50} = 7 \mu g/kg$  i.m., BuChE = 10.6 mg/kg to protect against  $3 \times LD_{50}$  of soman) based on calculations that assumed a one to one stoichiometric reaction (Fig. 1). At 1.5 h pre- $T_{max}$  after administration of enzyme, a blood sample was taken via the femoral vein, and the whole blood (BuChE) concentration was determined. Based on that determination, the total number of moles of BuChE (endogenous and administered HuBuChE) in circulation was calculated assuming a blood volume of 200 mL for a 3.0–3.5 kg monkey. An amount of soman (10.5  $\mu g/kg$ ) equal to



T=24



 $1.5 \times LD_{50}$  was given i.m. and the animal observed for signs of intoxication for 90 min. At the end of that period a second blood sample was taken, and the whole blood BuChE concentration redetermined. The total number of moles of BuChE in circulation was recalculated and  $2 \times LD_{50}$  of soman (14 µg/kg) was administered i.m. Again the animal was observed for signs of intoxication for 90 min, and if none were observed the process was repeated one more time. Twenty-four hours after the third dose of soman, a final blood sample was taken and analyzed for moles of HuBuChE.

## 3. Results

The pharmacokinetics of HuBuChE in guinea pigs followed a one-compartment model with a single elimination phase (Table 1, Fig. 2).

The pharmacokinetics of HuBuChE in cynomolgus monkeys also fit a one-compartment model with a single elimination phase (Table 2, Fig. 3).

Guinea pigs were pretreated with HuBuChE and 18–20 h later they were challenged with either soman or VX. The challenge design allowed for multiple challenges of experimental animals with lethal amounts of

Table 1

Pharmacokinetic parameters for HuBuChE in guinea pigs after i.m. administration

Parameter <sup>a</sup>	19.9 mg/kg HuBuChE	32.5 mg/kg HuBuChE	
$\overline{C_{\text{max}}}$ (mg/mL)	$0.015 \pm 0.0005$	$0.030 \pm 0.0008$	
$T_{\rm max}$ (h)	$26.0 \pm 2.55$	$26.8\pm2.32$	
AUC	$1.93 \pm 0.19$	$3.84 \pm 0.33$	
$T_{1/2}$ elimination (h)	$64.6 \pm 10.3$	$75.5 \pm 10.1$	

<sup>a</sup> Values for each pharmacokinetic parameter are expressed as mean  $\pm$  S.D. error (n = 3).



Fig. 2. Time-course of HuBuChE in blood after i.m. administration in guinea pigs: (●) 32.5 mg/kg dose of HuBuChE; (■) 19.9 mg/kg dose of HuBuChE.

#### Table 2

Pharmacokinetic parameters for HuBuChE in cynomolgus monkeys after i.m. administration

Parameter <sup>a</sup>	5.25 mg/kg HuBuChE	8.75 mg/kg HuBuChE	
$\overline{C_{\text{max}}}$ (mg/mL)	$0.030 \pm 0.005$	$0.047 \pm 0.0008$	
$T_{\rm max}$ (h)	$9.27\pm0.44$	$10.3 \pm 0.47$	
AUC	$3.68 \pm 0.13$	$5.46 \pm 0.19$	
$T_{1/2}$ elimination (h)	$79.3\pm3.8$	$73.5 \pm 3.5$	

<sup>a</sup> Values for each pharmacokinetic parameter are expressed as mean  $\pm$  S.D. error (n = 3).



Fig. 3. Time-course of HuBuChE in blood after i.m. administration in cynomolgus monkeys: ( $\bigcirc$ ) 5.25 mg/kg dose of HuBuChE; ( $\blacksquare$ ) 8.75 mg/kg dose of HuBuChE.

soman or VX until a total  $5.5 \times LD_{50}$  dose was given. This approach insured that the challenge with soman or VX occurred just prior to  $T_{max}$ . In the case of soman or VX challenge (n = 10/group) all guinea pigs survived with no observable signs (Table 3). At necropsy, either 7 days (n = 5) or 14 days (n = 5) post-soman challenge, all organs appeared normal and no abnormal histopathology was observed in Hematoxylin 2 and Eosin-Y (H&E) stained tissues. None of the animals in either of the challenge group received therapy in the form of atropine, 2-PAM or diazepam.

Monkeys were pretreated with HuBuChE, and 10–11 h later they were challenged with soman. The

Table 3							
Protection	by H	HuBuChE	against	nerve	agent	poisoning	

....

Species	Toxin	Dose (LD <sub>50</sub> )	Impairment	Recovery
Guinea pig	SOMAN	5.5	None	Immediate
Guinea pig	VX	5.5	None	Immediate
Cynomolgus	SOMAN	5.5	1/5	4/6 <sup>a</sup>

<sup>a</sup> One animal died after the third dose of soman and one was impaired, and later euthanized after 48 h. Remaining four animals were normal, survived and are being held for long-term observations. challenge design allowed for multiple challenges of experimental animals with lethal amounts of soman until a total  $5.5 \times LD_{50}$  dose was given. This approach ensured that the challenge with soman occurred just prior to  $T_{\text{max}}$ . In the case of soman challenge (n = 6), one animal died within 30 min of receiving the third dose of soman. Of the five survivors, all lived for 48 h, but one was deemed to be in distress at that time and was euthanized after evaluation by the attending veterinarian. The other four monkeys survived with no observable signs after any of the three doses of soman. None of the tissues from the non-surviving monkeys were subjected to necropsy or histological examination.

#### 4. Discussion

The pharmacokinetics of HuBuChE in guinea pigs were reported previously by Raveh et al. [16] following either i.m. or intravenous (i.v.) administration. In that study only a single dose of HuBuChE was administered. In the current study, we have carried out pharmacokinetic studies at two doses of HuBuChE. The lower dose, 19.9 µg/kg, is the dose of HuBuChE that would theoretically neutralize  $1.5 \times LD_{50}$  of soman, based on an LD<sub>50</sub> of 30 µg/kg i.m. The higher dose, 32 mg/kg, is theoretically capable of neutralizing  $2.5 \times LD_{50}$  of soman. Given that we planned to use even higher concentrations of HuBuChE in guinea pigs for our efficacy studies, it was necessary to ensure that the pharmacokinetics of the material were not altered by changes in dose in any unexpected manner. As can be seen (Table 1), the increases in  $C_{\text{max}}$  were dose dependent in a linear manner and T<sub>max</sub> was dose independent. The pharmacokinetic data following the administration of two doses of HuBuChE (5.25 mg/kg and 8.75 mg/kg equal to the theoretical amounts needed to neutralize 1.5 and  $2.5 \times LD_{50}$ of soman, respectively;  $1 \times LD_{50} = 8 \mu g/kg$ ) to cynomolgus monkeys yield results consistent with those found in guinea pigs (Table 2). Raveh et al. had determined the pharmacokinetics for HuBuChE in rhesus monkeys at one dose and found that by 75 h, most of the material had been eliminated with a mean retention time of 34 h (following i.v. administration) and a  $T_{\text{max}}$  of ~9.5 h [16]. While the cynomolgus monkeys exhibited similar  $T_{\text{max}}$  values for maximal absorption (10.3 h), the  $t_{1/2}$  of HuBuChE in this species was almost twice as long as previously reported in rhesus monkeys [16]. However, using the same preparation of HuBuChE administered i.v., a mean residence time of  $72 \pm 7$  h was observed in rhesus monkeys (Myers et al., unpublished results). Therefore, the pharmacokinetic profile of HuBuChE in the two macaque species is very similar.

To evaluate the efficacy of HuBuChE, guinea pigs or cynomolgus monkeys were pretreated with HuBuChE at doses calculated to protect against a challenge of  $8 \times LD_{50}$  of nerve agent. This dose was chosen based on previous data (Saxena et al., unpublished results) that not all the material injected i.m. was accounted for in the circulatory system of animals. The guinea pigs or monkeys in this study were challenged three times within a 4-h period (Fig. 1). In the case of guinea pigs, the first challenge dose of soman or VX was  $1.5 \times LD_{50}$ , respectively. The second and third challenges of soman or VX were  $2 \times LD_{50}$  at 2 and 4 h, respectively, following the initial challenge for a total challenge of  $5.5 \times LD_{50}$  for each agent. The time of challenge covered a 4-h period and was designed to occur at or just prior to the  $T_{\text{max}}$  as determined in the pharmacokinetic studies. Analysis of the data used to generate the best fit model for the determination of the pharmacokinetic constants showed that the HuBuChE plasma concentrations were essentially constant at  $T_{\text{max}} \pm 3.0$  h. Based on those results, the actual challenge of guinea pigs was carried out such that the final challenge dose of soman or VX was given within the time for  $C_{\text{max}}$  $(T_{\text{max}} \pm 3.0 \text{ h})$ . In the case of either soman or VX, all animals survived the entire challenge sequence, exhibiting no obvious ill effects. They were asymptomatic and did not require, nor receive, any therapeutic drugs such as atropine or 2-PAM. Necropsy results were normal and no abnormal histopathology by H&E staining was observed.

The monkeys in this study were also challenged three times within a 4-h period (Fig. 1). The first dose of soman was  $1.5 \times LD_{50}$ , The second and third challenges of soman were 2 × LD<sub>50</sub> at 2 and 4 h following the initial challenge for a total challenge of  $5.5 \times LD_{50}$  for each agent. As in the guinea pig studies the actual challenge of animals was carried out such that the final challenge dose of soman was given within the time for  $C_{\text{max}}$  ( $T_{\text{max}} \pm 3.0$  h). Of the six monkeys, all survived with no indication of adverse signs after two challenges of soman, a total of  $3.5 \times LD_{50}$  in a 2-h period. After the second injection of  $2 \times LD_{50}$  of soman, one animal exhibited signs of intoxication within 10 min and died within 2 h. A second animal was lethargic and remained so for over 48 h at which time he was euthanized at the recommendation of the attending veterinarian. The remaining four animals exhibited no adverse signs. They are still alive and are being monitored for any long-term effects.

Based on our results to date, we are encouraged by the extent of protection that can be afforded by the administration of the stoichiometric scavenger, HuBuChE.

The successful results in these experiments provide the type of efficacy data in two species as required under the US Food and Drug Administration animal rule and should allow for a subsequent investigational new drug submission.

The animal care programs of the US Army Medical Research Institute of Chemical Defense and Battelle are fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care. The animals used in this study were handled in accordance with the principles stated in the Guide for the Care and Use of Laboratory Animals proposed by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Research Council, DHHA, National Institutes of Health Publication 85-23, 1985 and the Animal Welfare Act of 1966, as amended.

## References

- [1] B.P. Doctor, D.M. Maxwell, Y. Ashani, A. Saxena, R.K. Gordon, New approaches to medical protection against chemical warfare nerve agents, in: S. Somani, J. Romano (Eds.), Chemical Warfare Agents: Toxicity at Low Levels, CRC Press, Boca Raton, 2001, pp. 191–214.
- [2] D.E. Lenz, C.A. Broomfield, D.M. Maxwell, D.M. Cerasoli, Nerve agent bioscavengers: protection against high- and low-dose organophosphorus exposure, in: S. Somani, J. Romano (Eds.), Chemical Warfare Agents: Toxicity at Low Levels, CRC Press, Boca Raton, 2001, pp. 215–243.
- [3] B.P. Doctor, Butyrylcholinesterase: its use for prophylaxis of organophosphate exposure, in: E. Giacobini (Ed.), Butyrylcholinesterase: its Function and Inhibitors, Martin Dunitz, London, New York, 2003, pp. 163–177.
- [4] M.A. Dunn, F.R. Sidell, Progress in medical defense against nerve agents, J. Am. Med. Assoc. 262 (1989) 649.
- [5] W. Erdmann, I. Bosse, P. Franke, Zur resorption und ausscheidung von toxigonin nach intramuskularer am menschen, Dtsch. Med. Wschr. 90 (1965) 1436.

- [6] W. Wiezorek, W. Kreisel, W. Schnitzlein, H. Matzkowski, Eigenwirkungen von trimedoxin und pralidoxim am menschen, Zeitschr. Militarmed. 4 (1968) 223.
- [7] F. Sidell, W. Groff, Toxigonin: blood levels and side effects after intramuscular administration in man, J. Pharm. Sci. 59 (1970) 793.
- [8] V. Vojvodic, Blood levels, urinary excretion and potential toxicity of *N*,*N'*-trimethylenebis (pyridinium-4-aldoxime) dichloride (TMB-4) in healthy man following intramuscular injection of the oxime, Pharmacol. Clin. 2 (1970) 216.
- [9] G.R. Wenger, Effects of physostigmine, atropine and scopolamine on behavior maintained by a multiple schedule of food presentation in the mouse, J. Pharmacol. Exp. Ther. 209 (1979) 137.
- [10] J.G. Clement, HI-6 reactivation of central and peripheral acetylcholinesterase following inhibition by soman, sarin and tabun in vivo in the rat, Biochem. Pharmacol. 31 (1982) 1283.
- [11] J.H. McDonough, D.M. Penetar, The effects of cholinergic blocking agents and anticholinesterase compounds on memory, learning and performance, in: M.Y. Spiegelstein, A. Levy (Eds.), Behavioral Models and the Analysis of Drug Action, Proceedings of the 27th OHOLO Conference, Elsevier, Amsterdam, 1982, p. 155.
- [12] B.B. Huff (Ed.), Physician's Desk Reference, Medical Economics Co. Inc., Oradell, 1986, p. 1491.
- [13] B.G. Talbot, D.R. Anderson, L.W. Harris, L.W. Yarbrough, W.J. Lennox, A comparison of in vivo and in vitro rates of aging of soman-inhibited erythrocyte acetylcholinesterase in different animal species, Drug Chem. Toxicol. 11 (1988) 289.
- [14] Y. Ashani, S. Shapira, D. Levy, A.D. Wolfe, B.P. Doctor, L. Raveh, Butyrylcholinesterase and acetylcholinesterase prophylaxis against soman poisoning in mice, Biochem. Pharmacol. 41 (1991) 37.
- [15] L. Raveh, J. Grunwald, D. Marcus, Y. Papier, E. Cohen, Y. Ashani, Human butyrylcholinesterase as a general prophylactic antidote for nerve agent toxicity, Biochem. Pharmacol. 45 (1993) 2465.
- [16] L. Raveh, E. Grauer, J. Grunwald, E. Cohen, Y. Ashani, The stoichiometry of protection against soman and VX toxicity in monkeys pretreated with human butyrylcholinesterase, Toxicol. Appl. Pharmacol. 145 (1997) 43.
- [17] G.L. Ellman, K.D. Courtney, V. Andres Jr., R.M. Featherstone, A new and rapid colorimetric determination of acetylcholinesterase activity, Biochem. Pharm. 7 (1961) 88–95.